TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05045482

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Saroglitazar Magnesium 1 mg
Description: Group-8: Total of 12 subjects will be enrolled in the Group-8. Group 8A (n=3, consist of mild hepatic impairment subjects); Group 8B (n=3, consist of moderate hepatic impairment), Group 8C (n=3, consist of severe hepatic impairment and Group 8D (n=3, consist of control subjects with normal hepatic functions).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Saroglitazar Magnesium 2 mg
Description: Group-9: Total of 12 subjects will be enrolled in the Group-9. Group 9A (n=3, consist of mild hepatic impairment subjects); Group 9B (n=3, consist of moderate hepatic impairment), Group 9C (n=3, consist of severe hepatic impairment and Group 9D (n=3, consist of control subjects with normal hepatic functions).
Study: NCT05730556

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Nerivio ®
Description: Non-invasive wearable, remote electrical neuromodulation (REN) device controlled by a smartphone application worn on an armband on the upper arm.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Nerivio ®
Description: Non-invasive wearable, remote electrical neuromodulation (REN) device controlled by a smartphone application worn on an armband on the upper arm.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sham
Description: Electrical stimulation to mimic study treatment intervention

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sham
Description: Electrical stimulation to mimic study treatment intervention
Study: NCT06129474

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Proton Pump Inhibitor deprescribing tool
Description: The intervention is targeted to the Swiss Primary care practice. It involves educational material and resources to guide the safe deprescribing of inappropriate PPIs, for both general practitioners and patients.
Study: NCT05658796

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: +RxWell
Description: During the SuRxgWell trial, if a participant is randomized to receive RxWell, they will be provided with an access code that is required to download the app. Once the participant has downloaded the app, they will be paired with a UPMC coach who will guide the person through the sessions using in-app texting to help give them the tools needed to actively cope with anxiety and/or depression. The UPMC coaches are supervised by a licensed UPMC mental health clinician. The participant will have access to the app and coach for six months after they have consented. The digital behavioral tool includes over 30 brief Cognitive Behavioral Therapy (CBT) and mindfulness-based techniques.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: -RxWell
Description: Treatment as usual
Study: NCT06130254

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adagrasib
Description: Given by PO BID

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olaparib
Description: Given by PO BID
Study: NCT05366088

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness-Based Cognitive Therapy
Description: MBCT is an 8-week therapy integrating formal mindfulness meditation (e.g. breath and body awareness) and informal mindfulness (e.g. eating, walking). Participants are taught to attend non-judgmentally to present moment experiences. MBCT includes cognitive therapy techniques to target the ruminative thought processes and identification with negative emotions seen in depression. MBCT teaches participants how to disengage from habitual (automatic) dysfunctional cognitive routines, in particular depression-related ruminative thought patterns that perpetuate depressive symptoms and increase vulnerability to relapse.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Health Enhancement Program
Description: HEP teaches health-enhancing techniques and was designed by University of Wisconsin and NIH as a manualized active control group program for mindfulness-based intervention trials (53,54). We have tailored HEP to be structurally equivalent to MBCT. HEP will be delivered by social workers (or equivalent) who have received the official training course from HEP's developers at the University of Wisconsin. Participants will learn about health promotion, healthy diet, music, and gentle exercise, but not about breathing techniques or meditation.
Study: NCT05132400

Intervention type: BEHAVIORAL
Intervention: Psychological-informed Physical Therapy (PiPT) Training
Description: An approach designed to incorporate the concepts of cognitive behavioral therapy (CBT) for pain management into routine clinical PT practice in order to modify maladaptive responses associated with chronicity. The goal of PiPT is to promote a fast and optimal recovery by removing psychological obstacles, obviating the need for referral to a psychologist and facilitating triage to other health professionals in a timely manner when needed. PiPT training includes education about the neuropsychology of pain, patient communication skills, and identification of psychosocial risk factors for chronicity and treatment approaches that include reassurance, relaxation, and psycho-behavioral reactivation.
Study: NCT05915195

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Postural and Kinesthetic Awarness
Description: Firstly, patient performed therapeutic activities/exercise to achieve balance in sitting position using chair with arm rest and with planted feet then progressed to sitting on chair without arm rest with proper feet placement. Once the patient achieved balance in sitting on chair then shifted to sitting on the stool and later standing in parallel bar that leads to balance training in independent standing.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Routine Physical Therapy
Description: Range of motion exercises (Active assisted), stretching exercises, strengthening and positioning.
Study: NCT05208606

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Wawokiya Health Advocate
Description: Study visits 1 and 2 will follow the same broad procedures. Subsequent visits will be structured around needs. WHAs will cover multiple domains of assessment utilizing a visit guide.~Visit 1: Specific topics covered in this visit will include; 1) an explanation of palliative care, study, and WHA role and 2) mapping of providers/family/caregivers The WHA will arrange dates and times for future visits.~Visit 2: Occurs 1 week after the first visit. WHAs will begin to assess patient needs utilizing a needs assessment tool. Specific topics covered will include: 1) Documentation of disease history 2) Needs assessment screen~Following Visits: After visit 2, activities will be based on needs assessed. Activities may entail: 1) Review of palliative care and WHA role, 2) Assessment of needs, 3) Addressing needs 3) Exploring goals of care.~We anticipate patients will receive an average of 2-3 WHA visits per month. Investigators will hold regular supervisory meetings with the WHA.
Study: NCT06463431

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Processing Therapy
Description: We propose a conceptual model for the relationship between PTSD, substance use, \& sexual risk behaviour wherein using substances to avoid posttraumatic cognitions \& affect leads to risky sexual behaviour through impaired safer sex negotiation. These mechanisms are consistent with the theory underlying CPT. Behaviourally, substance use (and potentially risky sexual behaviour) is negatively reinforced through avoiding unwanted negative affect. Cognitively, PTSD-based predictions may generate unrealistic risk appraisals that contribute to sexual risk. CPT addresses these specified pathways by a) identifying how trauma leads to maladaptive beliefs about the self, others, \& the future, b) cognitive interventions to address these beliefs, \& c) an overall trauma-focused orientation that addresses cognitive, affective \& behavioural avoidance, using cognitive restructuring to lead to more realistic/adaptive beliefs, less cognitive/affective avoidance, \& more goal-directed approach behaviours.
Study: NCT06091943

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tislelizumab IV
Description: Planned doses will be administered intravenously.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tislelizumab SC
Description: Planned doses will be administered via subcutaneous injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tislelizumab SC
Description: Planned doses will be administered via subcutaneous injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Histology-Based Chemotherapy Doublet
Description: Chemotherapy Doublet 1: Cisplatin/carboplatin + pemetrexed.~Chemotherapy Doublet 2: Carboplatin + paclitaxel/nab-paclitaxel.~Choice of histology-based induction chemotherapy doublet will be determined by the investigator and will be administered at standard doses intravenously.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Histology-Based Chemotherapy Doublet
Description: Chemotherapy Doublet 1: Cisplatin/carboplatin + pemetrexed.~Chemotherapy Doublet 2: Carboplatin + paclitaxel/nab-paclitaxel.~Choice of histology-based induction chemotherapy doublet will be determined by the investigator and will be administered at standard doses intravenously.
Study: NCT05532722

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABC008
Description: Given subcutaneous injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABC008
Description: Given subcutaneous injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABC008
Description: Given subcutaneous injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABC008
Description: Given subcutaneous injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABC008
Description: Given subcutaneous injection
Study: NCT05767398

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zanubrutinib
Description: Administered as a tablet or capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zanubrutinib
Description: Administered as a tablet or capsule
Study: NCT05018143

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: STARS
Description: This intervention will use an online mobile application for teach life skills, coupled with peer mentoring to support the use of safety planning.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control condition
Description: In this intervention, participants will receive the safety planning intervention.
Study: NCT05087563

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Neurolens spectacle lens
Description: spectacle lens

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo spectacle lens
Description: spectacle lens for refractive correction
Study: NCT05601765

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard communication pathways after discharge
Description: Standard communication pathways after discharge

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Digital team-based communication after discharge
Description: Standard communication pathways plus digital team-based communication after discharge
Study: NCT05091073

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NNC0385-0434
Description: All participants will be dosed with 40 mg oral NNC0385-0434 once-daily for 10 consecutive days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NNC0385-0434
Description: All participants will be dosed with 40 mg oral NNC0385-0434 once-daily for 10 consecutive days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: NNC0385-0434
Description: All participants will be dosed with 40 mg oral NNC0385-0434 once-daily for 10 consecutive days
Study: NCT04893395

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacogenomic Screening
Description: First telehealth appointment:~1. Pharmacogenomics education and informed consent~2. Medical history~3. Sample collection~Second telehealth appointment:~1. Results of pharmacogenomic testing~2. Utility and limitations of pharmacogenomic testing~3. Patient-specific potential impacts on current or future medication therapies~4. Answering of patient questions~5. Referral to mental health provider(s) for treatment-specific recommendations
Study: NCT05614700

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Brachytherapy
Description: High Dose-Rate Brachytherapy

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Sterotactic Body Radiotherapy
Description: Hypofractionated External Beam Radiotherapy
Study: NCT06416150

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Stage 1 HERS
Description: Participants will receive text message appointment reminders and barriers messages. Text messages will be sent on a prescheduled basis over the course of 2 weeks preceding the scheduled target appointment.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Stage 1 HERS
Description: Participants will receive text message appointment reminders and barriers messages. Text messages will be sent on a prescheduled basis over the course of 2 weeks preceding the scheduled target appointment.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Stage 1 HERS
Description: Participants will receive text message appointment reminders and barriers messages. Text messages will be sent on a prescheduled basis over the course of 2 weeks preceding the scheduled target appointment.
Study: NCT04839809

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CC-92480
Description: Oral
Study: NCT06498401

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: gut microbiota-targeted dietary intervention
Description: The dietary intervention targeted at gut microbiota. Each participant's dietary habits,food preferences and economic level were taken into account. The dietary intervention was delivered by sending meals. To ensure the freshness and quality of the ingredients, 2 dedicated researchers were jointly responsible for the procurement of fresh ingredients, which were purchased through regular channels on Monday, Wednesday and Friday mornings. Meals will be delivered three times a week for a 12-week intervention period. Guided dietary follow-up was conducted through WeChat or telephone follow-up. The researcher will provide cooking instruction or dietary pattern guidance every two weeks.
Study: NCT06474520

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Calculus bovis sativus (CBS)
Description: Subjects will orally receive 100mg CBS per day from day 1 to day 84.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Calculus bovis sativus (CBS)
Description: Subjects will orally receive 100mg CBS per day from day 1 to day 84.
Study: NCT05977816

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Negative Pressure Wound Therapy
Description: Application of a negative wound pressure therapy dressing to the wound post laparotomy

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard wound dressing
Description: Application of a standard wound dressing to the wound post laparotomy
Study: NCT05950932

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Melissa phytosome
Description: Melissa phytosome® is composed of dry extract of Berberis aristata root (550mg/cpr), complexed with phospholipids (soy lecithin), Pisum sativa proteins, and proanthocyanidin oligomers from Vitis vinifera. 2 tablets of 200 mg Melissa phytosome will be provided to participants, to be taken 30 minutes before bedtime for 14 days.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Melissa phytosome
Description: Melissa phytosome® is composed of dry extract of Berberis aristata root (550mg/cpr), complexed with phospholipids (soy lecithin), Pisum sativa proteins, and proanthocyanidin oligomers from Vitis vinifera. 2 tablets of 200 mg Melissa phytosome will be provided to participants, to be taken 30 minutes before bedtime for 14 days.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: 2 tablets with an equivalent form, color, flavor, and coating as the experimental product, to take 30 minutes before bedtime.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: 2 tablets with an equivalent form, color, flavor, and coating as the experimental product, to take 30 minutes before bedtime.
Study: NCT06273735

Intervention type: DIAGNOSTIC_TEST
Intervention: Pre- and postoperative determination of troponin as part of the study and 24-month FU survey
Description: An intervention is carried out as part of the normal clinical procedure regardless of the study measurement parameters.
Study: NCT04930861

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Covidir injections
Description: administration of the investigational product CODIVIR at a dose of 20 mg twice a day subcutaneously.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: One Step Test
Description: rapid test for the diagnosis of COVID-19 based on the detection of anti-SARS-CoV-2 in the blood.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: IgM and IgG dosage
Description: blood collection for dosage of Anti SARS-CoV-2 antibodies.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: RT-PCR SARS-CoV-2
Description: detection of viral RNA in nasopharyngeal and oropharyngeal samples by the Real Time Protein Chain Reaction technique.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Screening blood test
Description: complete blood count, urea, creatinine, uric acid, sodium, potassium, chloride, calcium, glucose, glycated hemoglobin, alkaline phosphatase (FA), alanine aminotransferase (ALT), aspartate aminotransferase (AST), total bilirubins and fractions ( BTF), total proteins and fractions (PTF), lipid profile (total cholesterol, fractions and triglycerides); coagulogram (TP, aPTT); D-dimer; C-reactive protein; HIV, HBV, HCV serology; Ferritin; fibrinogen, Pregnancy test for non-sterile women.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: ECG
Description: 12-lead electrocardiogram with report.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Medical evaluation
Description: evaluation by the principal investigator or assistant physician with a complete physical examination.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: NEWS-2 score
Description: assessment of the participant by the NEWS-2 score.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: WHO score
Description: assessment of the participant by the score of the World Health Organization.
Study: NCT05484973

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AMMA Portalbe Scalp Cooling System
Description: AMMA Portalbe Scalp Cooling System AMMA is indicated for use in chemotherapy infusion centers, during transit from the infusion center andat home and is intended for use by patients who are undergoing chemotherapy treatment and who want to reduce the likelihood of chemotherapy-induced alopecia.
Study: NCT05129657

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Product A
Description: Usual Brand (UB) filtered, non-menthol or menthol cigarette

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Product A
Description: Usual Brand (UB) filtered, non-menthol or menthol cigarette

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Product A
Description: Usual Brand (UB) filtered, non-menthol or menthol cigarette

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Product A
Description: Usual Brand (UB) filtered, non-menthol or menthol cigarette

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Product A
Description: Usual Brand (UB) filtered, non-menthol or menthol cigarette
Study: NCT04839809

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CC-92480
Description: Oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CC-92480
Description: Oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CC-92480
Description: Oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CC-92480
Description: Oral

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Oral
Study: NCT06432790

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: CHAMPION
Description: The CHAMPION program is an intensive health behavior and lifestyle treatment (IHBLT), formed through the integration of the Healthy Weight Clinic IHBLT and with MGB's pediatric Asthma Population Health Management Program. It consists of 30 hours of contact time with the CHAMPION team (physician, dietician, community health worker), consistent with the USPSTF and AAP recommendations, monthly individual clinic visits with the team (in person or virtual, per randomization), health coaching calls with a community health worker and/or registered dietician, monthly group sessions (in the first six months), and educational materials for families that reinforce healthy lifestyle behaviors and provide self-management education. In this study, all participants will participate in CHAMPION, but one arm will receive the experimental form (delivery via telehealth) and the other arm will receive the active comparator (delivery via telehealth).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CHAMPION
Description: The CHAMPION program is an intensive health behavior and lifestyle treatment (IHBLT), formed through the integration of the Healthy Weight Clinic IHBLT and with MGB's pediatric Asthma Population Health Management Program. It consists of 30 hours of contact time with the CHAMPION team (physician, dietician, community health worker), consistent with the USPSTF and AAP recommendations, monthly individual clinic visits with the team (in person or virtual, per randomization), health coaching calls with a community health worker and/or registered dietician, monthly group sessions (in the first six months), and educational materials for families that reinforce healthy lifestyle behaviors and provide self-management education. In this study, all participants will participate in CHAMPION, but one arm will receive the experimental form (delivery via telehealth) and the other arm will receive the active comparator (delivery via telehealth).
Study: NCT05711693

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Laser doppler vibrometry (LDV), heart(cordium) carotid pulse wave velocity (ccPWV)
Description: Patients scheduled for thoracic aorta MRI will have LDV measurement of ccPWV. Both techniques will be compared

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Blood pressure and heart rate measurement
Description: To all patients:~- blood pressure and heart rate will be measured

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: carotid to femoral PWW measurement
Description: To all patients:~- carotid to femoral PWW will be measured by LDV and tonometry for comparison

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Questionnaire completion
Description: All patients will complete a questionnaire of acceptability
Study: NCT04935177

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imlifidase
Description: Imlifidase is an immunoglobulin G (IgG)-degrading enzyme of Streptococcus pyogenes that is highly selective towards IgG. The cleavage of IgG generates one F(ab')2- and one homodimeric Fc-fragment and efficiently neutralizes Fc-mediated activities of IgG.